Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Dr Gao Weiwei

Dr Gao Weiwei

Guangdong Province Hospital for Women and Children Health Care, China

Title: Early HHHFNC versus NIPPV for primary respiratory support in preterm infants

Biography

Biography: Dr Gao Weiwei

Abstract

Background and Objective

There are limited data to inform the choice between early treatment with heated humidified high-flow nasal cannulae (HHHFNC) and early treatment with nasal intermittent positive pressure ventilation (NIPPV) as the initial support for preterm infants with respiratory distress syndrome(RDS).The objective was to assess the efficacy and safety of HHHFNC compared with NIPPV for preterm infants with RDS in our NICU.

Methods

In this prospective trial, infants, who were born between 28 weeks 0 days to 36 weeks 6 days of gestation, were randomized to HHHFNC or to NIPPV treatment initiated in the neonatal intensive care unit. The primary outcome was the incidence of intubation, defined as the need for intubation within 72 hours or within 7 days.

Results

A total of 208 infants were enrolled in the study. The incidence of intubation did not differ significantly between the two groups. The relative risks (RR) for the primary outcome of incidence of intubation within 72 hours or 7 days were 0.89 (95% CI, 0.37 to 2.11; p=0.79) and 0.00 (95% CI, 0.00 to 0.00), respectively. The rate of bronchopulmonary dysplasia in each of the two groups was similar (RR 1.49; 95% CI, 0.24 to 9.08; p=0.67). The rates of other adverse neonatal outcomes did not differ significantly between the two groups.

Conclusion

HHHFNC is an alternative to NIPPV for the early treatment of respiratory distress in preterm infants.